Authors urge primary care physicians to make case-by-case basis decisions based on benefit-to-risk<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
FRIDAY, Jan. 14, 2022 (HealthDay News) — Primary care providers should make individual decisions whether to prescribe aspirin based on a benefit-to-risk ratio, not simply age, according to a review published online Dec. 24 in Family Medicine and Community Health<\/em>.<\/p>\n Kyungmann Kim, Ph.D., from the University of Wisconsin-Madison, and colleagues conducted a systematic literature search to identify phase 3 randomized, double-blind placebo-controlled trials of aspirin in the primary prevention of cardiovascular disease (CVD) published in English between publication of the Antithrombotic Trialists (ATT) Collaboration meta-analysis (May 30, 2009) and July 31, 2021.<\/p>\n Based on the four identified trials added to the six from the ATT, the researchers found that aspirin produced a statistically significant 13 percent reduction in CVD, with similar benefits seen at older ages in each of the trials. With >10 percent absolute risk for CVD, benefits of aspirin generally outweighed risks for significant bleeding.<\/p>\n “Our perspective is that individual clinical judgments by primary care providers about prescription of aspirin in primary prevention of CVD should be based on our evidence-based solution of weighing all the absolute benefits and risks rather than age,” the authors write.<\/p>\n Several authors disclosed financial ties to pharmaceutical companies, including Bayer.<\/p>\n